國立虎尾科技大學 |

A Review of Bacteriophage Therapy for Pseudomonas aeruginosa Infections.

紀錄類型:	書目-語言資料,手稿 : Monograph/item
正題名/作者:	A Review of Bacteriophage Therapy for Pseudomonas aeruginosa Infections./
作者:	Hagen, Kyle.
面頁冊數:	1 online resource (67 pages)
附註:	Source: Masters Abstracts International, Volume: 58-01.
Contained By:	Masters Abstracts International58-01(E).
標題:	Microbiology. -
電子資源:	click for full text (PQDT)
ISBN:	9780438192409

A Review of Bacteriophage Therapy for Pseudomonas aeruginosa Infections.
Hagen, Kyle.

A Review of Bacteriophage Therapy for Pseudomonas aeruginosa Infections. - 1 online resource (67 pages)

Source: Masters Abstracts International, Volume: 58-01.

Thesis (M.S.)--Boston University, 2018.

Includes bibliographical references

With the spread of antibiotic resistance, alternative treatment methods for bacterial pathogens are needed. Pseudomonas aeruginosa is a Gram negative, opportunistic pathogen that is a common cause of healthcare associated infections and is listed as a critical priority for research and development of treatments by the Centers for Disease Control and Prevention. P. aeruginosa poses an increased risk to patients within the surgical or intensive care unit, patients with indwelling catheters, cystic fibrosis, and burn wound victims. With a paucity of antibiotics in the pipeline for Gram negative bacteria, phage therapy has reemerged as a potential treatment option. Bacteriophages were first discovered in 1917 by Felix d'Herelle, but by the end of World War II, they were all but forgotten in favor of antibiotics. Eastern European countries and the former Soviet Union continued to develop phage therapy since its discovery, but studies were not on par with today's standards. Recently the idea of phage therapy has reemerged in the Western world due to antibiotic resistance. In vitro and in vivo studies have shown that bacteriophages are easily isolated from the environment, with P. aeruginosa specific phages commonly found in hospital waste water and in sewage. Phage therapy has shown to be very effective at treating planktonic and biofilm forms of antibiotic resistant P. aeruginosa in vitro and in vivo. In humans, clinical trials are limited but phage therapy has successfully treated chronic otitis infections caused by P. aeruginosa and other studies have demonstrated the safety of phage therapy, reporting mild, if any, adverse effects. Bacteriophages may also synergize with several antibiotics, suggesting it may be beneficial to use them in conjunction to treat difficult or chronic infections. Additionally, P. aeruginosa bacteriophages may be beneficial in prophylactic treatment as well. When phages were combined with chlorine, a significant decrease in P. aeruginosa counts in chronic biofilms was observed, while also reducing its ability to form new biofilms. Similar results were noted when phages were applied to the lumen of catheters. These early results are promising for the future, but there are many steps that must be taken before starting new clinical trials and the widespread use of phage therapy begins.

Electronic reproduction.
Ann Arbor, Mich. :
ProQuest,
2018

Mode of access: World Wide Web

ISBN: 9780438192409Subjects--Topical Terms:

591510
Microbiology.
Index Terms--Genre/Form:

554714
Electronic books.

A Review of Bacteriophage Therapy for Pseudomonas aeruginosa Infections.
LDR:03565ntm a2200337Ki 4500 001 918995
005 20181106103645.5
006 m o u
007 cr mn||||a|a||
008 190606s2018 xx obm 000 0 eng d
020 $a 9780438192409
035 $a (MiAaPQ)AAI10751445
035 $a (MiAaPQ)bu:13564
035 $a AAI10751445
040 $a MiAaPQ $b eng $c MiAaPQ $d NTU
100 1 $a Hagen, Kyle. $3 1193464
245 1 2 $a A Review of Bacteriophage Therapy for Pseudomonas aeruginosa Infections.
264 0 $c 2018
300 $a 1 online resource (67 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Masters Abstracts International, Volume: 58-01.
500 $a Advisers: Matthew D. Layne; Gustavo Mostoslavsky.
502 $a Thesis (M.S.)--Boston University, 2018.
504 $a Includes bibliographical references
520 $a With the spread of antibiotic resistance, alternative treatment methods for bacterial pathogens are needed. Pseudomonas aeruginosa is a Gram negative, opportunistic pathogen that is a common cause of healthcare associated infections and is listed as a critical priority for research and development of treatments by the Centers for Disease Control and Prevention. P. aeruginosa poses an increased risk to patients within the surgical or intensive care unit, patients with indwelling catheters, cystic fibrosis, and burn wound victims. With a paucity of antibiotics in the pipeline for Gram negative bacteria, phage therapy has reemerged as a potential treatment option. Bacteriophages were first discovered in 1917 by Felix d'Herelle, but by the end of World War II, they were all but forgotten in favor of antibiotics. Eastern European countries and the former Soviet Union continued to develop phage therapy since its discovery, but studies were not on par with today's standards. Recently the idea of phage therapy has reemerged in the Western world due to antibiotic resistance. In vitro and in vivo studies have shown that bacteriophages are easily isolated from the environment, with P. aeruginosa specific phages commonly found in hospital waste water and in sewage. Phage therapy has shown to be very effective at treating planktonic and biofilm forms of antibiotic resistant P. aeruginosa in vitro and in vivo. In humans, clinical trials are limited but phage therapy has successfully treated chronic otitis infections caused by P. aeruginosa and other studies have demonstrated the safety of phage therapy, reporting mild, if any, adverse effects. Bacteriophages may also synergize with several antibiotics, suggesting it may be beneficial to use them in conjunction to treat difficult or chronic infections. Additionally, P. aeruginosa bacteriophages may be beneficial in prophylactic treatment as well. When phages were combined with chlorine, a significant decrease in P. aeruginosa counts in chronic biofilms was observed, while also reducing its ability to form new biofilms. Similar results were noted when phages were applied to the lumen of catheters. These early results are promising for the future, but there are many steps that must be taken before starting new clinical trials and the widespread use of phage therapy begins.
533 $a Electronic reproduction. $b Ann Arbor, Mich. : $c ProQuest, $d 2018
538 $a Mode of access: World Wide Web
650 4 $a Microbiology. $3 591510
650 4 $a Virology. $3 644995
655 7 $a Electronic books. $2 local $3 554714
690 $a 0410
690 $a 0720
710 2 $a ProQuest Information and Learning Co. $3 1178819
710 2 $a Boston University. $b Medical Sciences GMS. $3 1181317
773 0 $t Masters Abstracts International $g 58-01(E).
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10751445 $z click for full text (PQDT)